UNSPSC 51171978: Pinaverium

This classification denotes a gastrointestinal drug with the molecular formula C26H41BrNO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U2368VVE7O, chemically known as 4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-[2-[2-(6,6-dimethyl-4-bicyclo[3.1.1]heptanyl)ethoxy]ethyl]morpholin-4-ium, and which bears US NIH Compound Identifier 40704. European Medicines Agency schedules PINAVERIUM in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03826MIG.

As of Q4 2014, PINAVERIUM remains the US FDA Preferred Term for this commodity. SMILES: CC1(C2CCC(C1C2)CCOCC[N+]3(CCOCC3)CC4=CC(=C(C=C4Br)OC)OC)C.

UNSPSC 51171978 Pinaverium (Commodity) describes pharmaceutical products procured for state and local government health, corrections, and human services programs. Recent solicitations show state and local buyers acquiring pinaverium and similar pharmaceutical inventory through bulk purchasing agreements, direct-to-manufacturer contracts, and cooperative purchasing vehicles that serve multiple jurisdictions and agencies. Work currently being solicited includes supply of generic pharmaceuticals and OTC products to authorized wholesalers for distribution across state facilities, therapeutic pharmacy initiatives exploring direct manufacturer relationships to improve prescription fulfillment and cost control, and pharmaceutical products for correctional and community supervision drug-testing programs. Issuing bodies span state health and human services commissions, county corrections departments, and multistate cooperative purchasing alliances administering agreements on behalf of dozens of participating state and local government entities.

Minnesota's Multistate Cooperative Purchasing Alliance (MMCAP) and the Texas Health and Human Services Commission dominate recent activity under this code, reflecting the scale of multistate pharmaceutical procurement and state-level pharmacy benefit initiatives. The Minnesota Department of Administration issued RFP S1070000015802 on January 20, 2026, seeking generic multi-source pharmaceuticals and OTC products for distribution across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026, and contract effectiveness July 1, 2026. Texas HHS issued an exploratory RFI (HHS0017013) in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling the state's intent to develop direct contracting approaches outside traditional pharmacy benefit manager and group purchasing organization channels. Collin County Community Supervision and Corrections Department in Texas posted RFP 2026-327 on July 9, 2026, soliciting offender specimen collection and drug testing services valued at $600,000 over two years with three optional one-year renewals, with proposals due July 23, 2026. Recent activity concentrates in Texas and Minnesota, with multistate cooperative agreements extending to Oregon and beyond.